Know-how Spotlight| Article
Microfluidic know-how permits high-throughput, droplet-based antibody discovery in totally human antibody mice.
Antibody discovery analysis paves the way in which for brand new therapeutics. The seek for the correct antibody for a particular therapeutic utility necessitates a number of iterations of antibody manufacturing and screening. Throughout this course of, researchers check and re-test the operate of candidate antibodies, which is a resource-heavy and laborious endeavor.
Combining microfluidics single B cell know-how with totally human antibody transgenic mice permits totally human antibody discovery.
Biointron
Conventional approaches, whereas tried and examined, current sure challenges. For instance, hybridoma antibody screening, which includes fusing myeloma cells with antigen-activated B cells after which screening for goal antibody manufacturing, is a multi-step and time-consuming course of. Furthermore, whereas conventional approaches use mice which were genetically modified to supply human antibodies, these antibodies should not utterly encoded by human genes and are, subsequently, not thought of totally human.
Microfluidic know-how permits particular person plasma B cells to be encapsulated in microdroplets and screened at excessive velocity. This method permits high-throughput, single-cell degree evaluation, guaranteeing researchers can display huge numbers of antibodies whereas retaining excessive specificity and affinity for goal antigens.
Finest practices in antibody discovery additionally necessitate the manufacturing of totally human antibodies to make sure that scientists determine those who have excessive affinity and specificity for focused human antigens. From a translational perspective, totally human antibodies have higher security and tolerance profiles as a result of they’re much less more likely to elicit an undesirable immune response in sufferers.
In consequence, scientists search new and modern choices that allow safer, simpler, and streamlined antibody discovery workflows. Amongst such approaches is Biointron’s high-throughput totally human antibody discovery platform. Mixed with Cyagen’s HUGO-Ab™ totally human antibody transgenic mouse mannequin, Biointron’s AbDrop™ know-how permits microdroplet-based high-throughput screening of particular person B cells by the thousands and thousands. This method halves the standard six-month discovery timeline to 3 months and affords an environment friendly and dependable next-generation platform for totally human antibody discovery.
Study extra about safer and extra environment friendly totally human antibody discovery.
What’s the largest problem you encounter when performing antibody discovery screening?
